As drugs targeting respiration, such as metformin, are already being tested in tumor patients, it may be possible to block OXPHOS in patients with IDH mutations or reduced L-2-HG-dehydrogenase activity to relieve immunosuppression. This evidence concerns the gene IDH2 and neoplasm.